Atezolizumab in Combination with Bevacizumab

Atezolizumab in Combination with Bevacizumab in Untreated mRCC: Updated Analysis of IMmotion150 Study [LBA39]
Powles T, et al. 

The efficacy and safety of atezolizumab (anti-PD-L1) + bevacizumab (anti-VEGF) compared to sunitinib (TKI) in first-line (1L) metastatic renal-cell carcinoma (mRCC) were studied in the open-label, randomized, phase II IMmotion150 study (NCT01984242). Primary analysis (median follow-up, 20.7 mo) was previously reported at ASCO GU 2017. Updated analysis (median follow-up, 25.7 mo) has just been presented at ESMO 2017.

This updated analysis showed clinically meaningful benefit in PFS with atezolizumab + bevacizumab vs. sunitinib in both PD-L1+ and ITT patients. No new safety signals were detected with this updated analysis.

Data showing investigator (INV)-assessed PFS in both PD-L1+ and ITT patients are summarized as below:

*PD-L1+ was defined as PD-L1 expression ≥ 1% on tumor-infiltrating immune cells (IC) measured by VENTENA SP142 IHC assay.

These data supported the combination use of atezolizumab (anti-PD-L1) + bevacizumab (anti-VEGF) in 1L mRCC. Clinical benefit of this combination did not come at the expense of increased symptom burden. This combination will be further evaluated in the ongoing phase III IMmotion151 study (NCT02520821).


Felix Choi
Associate Manager, Medical Affairs
Cancer Immunotherapy